

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, C12N 9/00, 9/20		A1	(11) International Publication Number: WO 98/05349 (43) International Publication Date: 12 February 1998 (12.02.98)
(21) International Application Number: PCT/US97/13550 (22) International Filing Date: 31 July 1997 (31.07.97) (30) Priority Data: 08/691,479 2 August 1996 (02.08.96) US 08/714,744 16 September 1996 (16.09.96) US		(81) Designated States: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(71) Applicant (<i>for all designated States except US</i>): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). (72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): TOBIN, Frank, L. [US/US]; 2964 Dorman Avenue, Broomall, PA 19008 (US). SCHMIDT, Carl, J. [US/US]; 422 Crump Road, Exton, PA 19341 (US). WILKINSON, Francis, E. [US/US]; 307 Charleston Greene, Malvern, PA 19355 (US). (74) Agents: HAN, William, T. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).			
(54) Title: A NOVEL METHOD OF DETECTING AND TREATING CANCER (57) Abstract <p>The present invention provides a new method for diagnosing and treating cancers or BPH. Further provided are therapeutic agents and pharmaceutical compositions for treating cancers and BPH.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CP	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A NOVEL METHOD OF DETECTING AND TREATING CANCER**RELATED APPLICATION:**

This application is a continuation-in-part application of USSN 08/714,744, filed September 16, 1996, which is also continuation-in-part of USSN 08/691,479, filed August 2, 1996. The above mentioned patent applications are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

This invention relates, in part, to newly developed assay for diagnosing cancers, particularly prostate cancer, and benign prostate hyperplasia (BPH), and methods for identifying agents which modulate PLA₂ activity and therapeutic agents that modulate PLA₂ activity for treating cancers and BPH.

BACKGROUND OF THE INVENTION

Cancer of the prostate is the most prevalent malignancy in adult males, excluding skin cancer, and is an increasingly prevalent health problem in the United States. In 1994, it was estimated that in the US, 38,000 deaths resulted from this disease, indicating that prostate cancer is second only to lung cancer as the most common cause of death in the same population. If diagnosed and treated early, when the cancer is still confined to the prostate, the chances of cure is significantly higher. Accordingly, there is a great need for sensitive methods for the detection of organ-confined prostate cancer.

Extracellular Phospholipase A₂ (PLA₂) enzymes appear to mediate a variety of responses including cellular proliferation, chemotaxis and inflammation. There are two major groups of extracellular PLA₂ enzymes: pancreatic or group I and rheumatoid arthritis synovial fluid (RASF) or group II. The group I enzyme functions in digestion and also in modulating proliferation and chemotaxis. Currently, RASF-PLA₂ is predominantly thought to play a role in inflammatory responses including arthritis, septic shock and lung injury. The level of RASF-PLA₂ is regulated at the mRNA level by a variety agents including interleukin-6, interleukin-1 and tumor necrosis factor, all of which are involved in inflammatory

responses. While elevated levels of PLA₂ enzyme activity have been reported in a prostate cancer tissue in rats (F.H. Faas et al., The Journal of Urology, Vol 156, 243-248, 1996), there do not appear to be any reports of alterations of RASF-PLA₂ mRNA or polypeptide level in prostate cancer or benign prostate hyperplasia in humans.

5 Northern blot analysis was done on equivalent amounts of mRNA isolated from prostate cancer (PC), benign prostatic hyperplasia (BPH) and normal prostate (NP) according to methods published in Maniatis (MOLECULAR CLONING Maniatis, et. al., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).

10 Probe was synthesized from the full length cDNA encoding RASF-PLA₂. Results indicated the following ratios of RASF-PLA₂ mRNA: 10: 0.25: 1 for PC, BPH and NP, respectively. Loading differences were normalized using actin mRNA levels. The result showed that RASF-PLA₂ appears to be upregulated in prostate cancer and potentially downregulated in BPH.

15 As used hereinbelow "PLA₂" refers to group II or RASF-PLA₂.

SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the present invention to provide a new method for diagnosing, treating, and monitoring progression, remission 20 or recurrence of various forms of abnormal cell growth, such as cancers, particularly prostate cancer, and benign prostate hyperplasia (BPH). Further provided are methods to screen for therapeutic agents and pharmaceutical compositions for treating abnormal cell growth, such as cancers, particularly prostate cancer, and BPH. Further provided is the utilization of such agents or compositions for the treatment of 25 cancer, particularly prostate cancer, and BPH.

Thus, in accordance with one aspect of the present invention there are provided methods of screening for compounds which bind to and inhibit activation of the PLA₂.

In accordance with another aspect of the present invention there is provided a method of using such inhibiting compounds for treating conditions associated with 30 over-expression of the PLA₂.

In accordance with yet another aspect of the present invention, there are provided PLA₂ antagonists (inhibitors). Among the preferred antagonists are those

which mimic PLA₂ so as to bind to PLA₂ binding molecules but not elicit a PLA₂-induced response or more than one PLA₂-induced response. Also among the preferred antagonists are molecules that bind to or interact with PLA₂ so as to inhibit an effect of PLA₂ or more than one effect of PLA₂ or which prevent expression of PLA₂.

5 Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the
10 disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

DESCRIPTION OF THE INVENTION

15 The present invention relates to diagnostic assays, both quantitative and qualitative for detecting levels of PLA₂ protein or PLA₂ mRNA in cells, tissues and bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for detecting over-expression of PLA₂ protein compared to normal control bodily fluids or tissue
20 samples may be used to detect the presence of cancers, including prostate cancer. Further, the present method of quantifying protein PLA₂ protein level is particularly useful for discriminating between BPH and prostate cancer, since the existing methods such as prostatic specific antigen (PSA), digital examination, and transurethral ultrasound tests have difficulty discriminating between prostate cancer and BPH. For
25 example, the existing PSA diagnostic tests detect 20-28% of BPH patients and 62-81% of prostate cancer patients with PSA blood levels above approximately 99% of the normal population. Assay techniques that can be used to determine levels of gene expression, such as PLA₂ of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include
30 radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses and ELISA assays. Among these, ELISAs are

frequently preferred to detect a gene's expressed protein in biological fluids. An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to PLA₂, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to PLA₂. The

5 reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to PLA₂ is incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites

10 on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time PLA₂ binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to PLA₂ and linked to horseradish peroxidase is placed in the dish resulting in binding of the
15 reporter antibody to any monoclonal antibody bound to PLA₂. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to PLA₂ antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of PLA₂ protein present in the
20 sample. Quantitative results typically are obtained by reference to a standard curve. Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the disease is one in which blood levels are higher than three standard deviations above the mean blood level for a normal healthy population of individuals (99.86% of the population).

25 A competition assay may be employed wherein antibodies specific to PLA₂ attached to a solid support and labeled PLA₂ and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of PLA₂ in the sample.

Nucleic acid methods may be used to detect PLA₂ mRNA as a marker for
30 BPH and cancer, particularly prostate cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for

diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA

- 5 (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

- Hybridization to clones arrayed on a grid (i.e. gridding) can be used to both
- 10 detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the PLA₂ gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. DNA encoding the PLA₂ clone is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA)
- 15 copy of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound clone and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal
- 20 from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

- The above tests can be carried out on samples derived from patients' bodily fluids and tissue extracts (homogenates or solubilized tissue) such as from blood.
- 25 urine, saliva, tissue biopsy and autopsy material.

Antibodies

- The PLA₂ polypeptide, its fragments or other derivatives, or analogs thereof, or cells expressing them can be used as an immunogen to produce antibodies thereto.
- 30 These antibodies can be, for example, polyclonal or monoclonal antibodies. The present invention also includes chimeric, single chain, and humanized antibodies, as

well as Fab fragments, or the product of a Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.

Antibodies generated against PLA₂ can be obtained by direct injection of the polypeptide into an animal or by administering the polypeptide to an animal,

5 preferably a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies binding the whole native polypeptide.

For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include
10 the hybridoma technique (Kohler, G. and Milstein, C., *Nature* 256:495-497 (1975)), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., *Immunology Today* 4:72 (1983)) and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985)).

15 Techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies to immunogenic PLA₂.

20 Thus, among others, antibodies against PLA₂ may be employed to treat/inhibit various forms of cancer, including prostate cancer, and BPH.

PLA₂ binding molecules and assays

25 PLA₂ could be used to isolate proteins which interact with it and this interaction could be a target for interference. Inhibitors of protein-protein interactions between PLA₂ and other factors could lead to the development of pharmaceutical agents for the modulation of PLA₂ activity. As used herein, the term "modulate" refer to affecting the PLA₂ function.

30 Thus, this invention also provides a method for identification of binding molecules to PLA₂. Genes encoding proteins for binding molecules to PLA₂ can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Such methods are described in many laboratory manuals

such as, for instance, Coligan et al., Current Protocols in Immunology 1 (Rivett, A.J. *Biochem. J.* 291:1-10 (1993)); Chapter 5 (1991).

For example, the yeast two-hybrid system provides methods for detecting the interaction between a first test protein and a second test protein, *in vivo*, using

5 reconstitution of the activity of a transcriptional activator. The method is disclosed in U.S. Patent No. 5,283,173; reagents are available from Clontech and Stratagene. Briefly, PLA₂ cDNA is fused to a Gal4 transcription factor DNA binding domain and expressed in yeast cells. cDNA library members obtained from cells of interest are fused to a transactivation domain of Gal4. cDNA clones which express proteins
10 which can interact with PLA₂ will lead to reconstitution of Gal4 activity and transactivation of expression of a reporter gene such as *Gal4-lacZ*.

An alternative method is screening of λgt11, λZAP (Stratagene) or equivalent cDNA expression libraries with recombinant PLA₂. Recombinant PLA₂ protein or fragments thereof are fused to small peptide tags such as FLAG, HSV or
15 GST. The peptide tags can possess convenient phosphorylation sites for a kinase such as heart muscle creatine kinase or they can be biotinylated. Recombinant PLA₂ can be phosphorylated with ³²P or used unlabeled and detected with streptavidin or antibodies against the tags. λgt11cDNA expression libraries are made from cells of interest and are incubated with the recombinant PLA₂, washed
20 and cDNA clones isolated which interact with PLA₂. See, e.g., T. Maniatis et al., *supra*.

Another method is the screening of a mammalian expression library in which the cDNAs are cloned into a vector between a mammalian promoter and polyadenylation site and transiently transfected in COS or 293 cells followed by
25 detection of the binding protein 48 hours later by incubation of fixed and washed cells with a labelled PLA₂, preferably iodinated, and detection of bound PLA₂ by autoradiography. See Sims et al., *Science* 241:585-589 (1988) and McMahan et al., *EMBO J.* 10:2821-2832 (1991). In this manner, pools of cDNAs containing the cDNA encoding the binding protein of interest can be selected and the cDNA of
30 interest can be isolated by further subdivision of each pool followed by cycles of transient transfection, binding and autoradiography. Alternatively, the cDNA of interest can be isolated by transfecting the entire cDNA library into mammalian cells

and panning the cells on a dish containing PLA₂ bound to the plate. Cells which attach after washing are lysed and the plasmid DNA isolated, amplified in bacteria, and the cycle of transfection and panning repeated until a single cDNA clone is obtained. See Seed *et al.*, *Proc. Natl. Acad. Sci. USA* 84:3365 (1987) and Aruffo *et*

5 *al.*, *EMBO J.* 6:3313 (1987). If the binding protein is secreted, its cDNA can be obtained by a similar pooling strategy once a binding or neutralizing assay has been established for assaying supernatants from transiently transfected cells. General methods for screening supernatants are disclosed in Wong *et al.*, *Science* 228:810-815 (1985).

10 Another alternative method is isolation of proteins interacting with PLA₂ directly from cells. Fusion proteins of PLA₂ with GST or small peptide tags are made and immobilized on beads. Biosynthetically labeled or unlabeled protein extracts from the cells of interest are prepared, incubated with the beads and washed with buffer. Proteins interacting with PLA₂ are eluted specifically from the beads
15 and analyzed by SDS-PAGE. Binding partner primary amino acid sequence data are obtained by microsequencing. Optionally, the cells can be treated with agents that induce a functional response such as tyrosine phosphorylation of cellular proteins. An example of such an agent would be a growth factor or cytokine such as interleukin-2.

20 Another alternative method is immunoaffinity purification. Recombinant PLA₂ is incubated with labeled or unlabeled cell extracts and immunoprecipitated with anti- PLA₂ antibodies. The immunoprecipitate is recovered with protein A-Sepharose and analyzed by SDS-PAGE. Unlabelled proteins are labeled by biotinylation and detected on SDS gels with streptavidin. Binding partner proteins
25 are analyzed by microsequencing. Further, standard biochemical purification steps known to those skilled in the art may be used prior to microsequencing.

Yet another alternative method is screening of peptide libraries for binding partners. Recombinant tagged or labeled PLA₂ is used to select peptides from a peptide or phosphopeptide library which interact with PLA₂. Sequencing of the
30 peptides leads to identification of consensus peptide sequences which might be found in interacting proteins.

PLA₂ binding partners identified by any of these methods or other methods which would be known to those of ordinary skill in the art as well as those putative binding partners discussed above can be used in the assay method of the invention.

Assaying for the presence of PLA₂/binding partner complex are accomplished by,

5 for example, the yeast two-hybrid system, ELISA or immunoassays using antibodies specific for the complex. In the presence of test substances which interrupt or inhibit formation of PLA₂/binding partner interaction, a decreased amount of complex will be determined relative to a control lacking the test substance.

Assays for free PLA₂ or binding partner are accomplished by, for example,

10 ELISA or immunoassay using specific antibodies or by incubation of radiolabeled PLA₂ with cells or cell membranes followed by centrifugation or filter separation steps. In the presence of test substances which interrupt or inhibit formation of PLA₂/binding partner interaction, an increased amount of free PLA₂ or free binding partner will be determined relative to a control lacking the test substance.

15 Polypeptides of the invention also can be used to assess PLA₂ binding capacity of PLA₂ binding molecules in cells or in cell-free preparations.

Agonists and antagonists - assays and molecules

The PLA₂ may be employed in a process for screening for compounds which 20 either inhibit, promote or modulate the enzymatic activity of PLA₂. One standard assay for PLA₂ uses [linoleoyl-1-¹⁴C] labeled L- α -1-acyl-2-linoleoylphosphatidylethanolamine as a substrate and follows the release of ¹⁴C labeled free fatty acid. This assay or others could be used to identify either agonists or antagonists of PLA₂.

25 Examples of potential PLA₂ antagonists are small molecules such as organic molecules or peptides, antibodies, or in some cases an oligonucleotide, which binds to PLA₂ and prevents enzymatic activity.

Potential antagonists also include small molecules or proteins which are closely related to the binding molecules of the PLA₂, e.g. a fragment of the binding 30 molecules, which have lost biological function, and when bind to the PLA₂ polypeptide inhibit its activity. ("Binding molecules" as used herein refer to molecules that specifically bind to or interact with PLA₂ polypeptide of the present invention.

Included in the definition of binding molecules are other factors, co-factors, units or subunits which enhance PLA₂ activity or diminish it. Such binding molecules are a part of the present invention. Binding molecules also may be non-naturally occurring, such as antibodies and antibody-derived reagents that bind specifically to PLA₂.)

5 A potential antagonist also includes an antisense construct prepared through the use of antisense technology. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes for the mature PLA₂,

10 is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix -see Lee et al., *Nucl. Acids Res.*, 6:3073 (1979); Cooney et al., *Science*, 241:456 (1988); and Dervan et al., *Science*, 251:1360 (1991)), thereby preventing transcription and the production of PLA₂ polypeptide.

15 The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the PLA₂ polypeptide (antisense - Okano, *J. Neurochem.*, 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be

20 expressed *in vivo* to inhibit production of the PLA₂ polypeptide. Included in this delivery is by gene therapy.

Another potential antagonist is a small molecule which binds to the PLA₂ making it inaccessible to binding molecules (e.g. substrates) such that normal biological activity is prevented. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules and organic compounds.

PLA₂ are ubiquitous in the animal host and are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drugs which can inhibit the function of a PLA₂.

This invention additionally provides a method of treating an abnormal condition related to an excess of PLA₂ activity, such as BPH and various forms of cancer, including prostate cancer, which comprises administering to a subject the inhibitor compounds (antagonists) as hereinabove described along with a

pharmaceutically acceptable carrier in an amount effective to inhibit PLA₂ activity directly or by blocking binding of binding molecules to PLA₂ polypeptide.

Compositions and Kits

5 The compounds which inhibit such PLA₂, may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation should
10 suit the mode of administration.

The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Administration

15 Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or
20 intradermal routes, among others.

The pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific indication or indications. In general, the compositions are administered in an amount of at least about 10 µg/kg body weight. In most cases they will be administered in an amount not in excess of
25 about 8 mg/kg body weight per day. Preferably, in most cases, dose is from about 10 µg/kg to about 1 mg/kg body weight, daily. It will be appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like.

30

Vaccine

Another aspect of the invention relates to a method for inducing an immunological response in an animal, particularly in a mammal, which comprises inoculating the animal with PLA₂, or a fragment or variant thereof, adequate to produce antibody to protect said animal from BPH or various forms of cancer.

5 including prostate cancer. Yet another aspect of the invention relates to a method of inducing immunological response in an animal which comprises, through gene therapy, delivering gene encoding PLA₂, or a fragment or a variant thereof, for expressing PLA₂, or a fragment or a variant thereof *in vivo* in order to induce an immunological response to produce antibody to protect said animal from disease.

10 Further aspect of the invention relates to an immunological composition which, when introduced into an animal, particularly mammalian host, induces an immunological response in that animal to a given PLA₂ gene or protein coded therefrom, wherein the composition comprises a recombinant PLA₂ gene or protein coded therefrom comprising DNA which codes for and expresses an antigen of said
15 PLA₂ gene or protein coded therefrom.

The PLA₂ or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-
20 protein, such as Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilize the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

25 The present invention also includes a vaccine formulation which comprises the immunogenic recombinant protein together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and
30 non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include

suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Whilst the invention has been described with reference to PLA₂, it is to be understood that this covers fragments of the naturally occurring protein and similar proteins (for example, having sequence homologies of 50% or greater) with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant protein.

The present invention also provides a method for the production of transgenic animals with altered PLA₂ levels for the production of animals bearing PLA₂ induced diseases. Transgenic, non-human, animals may be obtained by transfected appropriate fertilized eggs or embryos of a host with nucleic acids encoding the PLA₂ disclosed herein, see for example U.S. Patents 4,736,866; 5,175,385; 5,175,384 and 5,175,386. The resultant transgenic animal may be used as a model for the study of altered PLA₂ levels. Particularly, useful transgenic animals are those which display a detectable phenotype associated with the altered expression of the PLA₂ polypeptide. Drugs may then be screened for their ability to reverse or exacerbate the relevant phenotype.

EXAMPLES

The present invention is further described by the following examples. The examples are provided solely to illustrate the invention by reference to specific embodiments. These exemplification's, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

All examples are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following examples can be carried out as

described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), herein referred to as "Sambrook."

All parts or amounts set out in the following examples are by weight, unless

5 otherwise specified.

Unless otherwise stated size separation of fragments in the examples below is carried out using standard techniques of agarose and polyacrylamide gel electrophoresis ("PAGE") in Sambrook and numerous other references such as, for instance, by Goeddel et al., *Nucleic Acids Res.* 8:4057 (1980).

10 **Example 1**

mRNA is prepared from normal and cancerous prostate tissue, size fractionated on an agarose gel and then transferred to a nylon membrane (northern blot). This blot is then hybridized to a PLA₂ specific cDNA probe that has been labeled with radioactive 15 [³²P]-dCTP. Following incubation, the blot is then washed under stringent conditions (described in Sambrook) and then exposed to film. Changes in mRNA levels as a function of disease will be seen as a change in intensity of the signal seen in diseased versus normal tissue.

20 **Example 2**

Below are the results from the PLA₂ levels in serum as found by an ELISA assay.

25 A. Normal healthy men without prostate disease (17 individuals): 4.85 ng/ml \pm 3.29

B. Normal healthy women (20 individuals): 5.31 ng/ml \pm 3.44

30 C. Combined normal healthy men and women (37 individuals): 5.11 ng/ml \pm 3.33

D. Patients with progressive prostate cancer (10 individuals): 32.65 ng/ml \pm 18.7

35 Eight (80%) of ten patients with progressive prostate cancer had PLA₂

blood levels at least three standard deviations above the combined mean of normal healthy men and women.

5 E. Patients with prostate cancer in remission (10 individuals): 7.77 ng/ml
 \pm 8.67

10 Only one of nine (11.1%) patients with prostate cancer in remission had PLA₂ blood levels at least three standard deviations above the combined mean of normal healthy men and women.

15 F. Patients with stabilized prostate cancer (5 individuals): 8.74 ng/ml \pm 8.12

20 G. Patients with benign prostate hypertrophy (13 individuals): 4.59 ng/ml
 \pm 3.29

25 H. Patients with prostatitis (7 individuals): 8.47 ng/ml \pm 9.73

30 Only one of seven (14.3%) patients with prostatitis had PLA₂ blood levels at least three standard deviations above the combined mean of normal healthy men and women.

What is claimed is:

1. A method for the treatment of cancer comprising: administering to the patient a therapeutically effective amount of the PLA₂ antagonist.
2. The method of treatment of claim 1 in which cancer is prostate cancer.
3. A diagnostic method for a cancer comprising:
analyzing for the abnormally high level of PLA₂ polypeptide in cells, tissues and bodily fluids of an individual with prostate cancer.
4. The diagnostic method of claim 3 in which cancer is prostate cancer.
5. A diagnostic method for discriminating between prostate cancer and BPH or normal prostate tissue comprising:
analyzing for the abnormally high level of PLA₂ polypeptide in cells, tissues and bodily fluids of an individual with prostate cancer.
6. A method of claim 3 in which the diagnostic process involves ELISA.
7. A method of claim 3 in which the diagnostic process is immunohistochemistry.
8. A diagnostic method for a cancer or BPH comprising:
analyzing for the abnormally high or low transcription level of PLA₂.
9. The method of claim 8 which is Northern blot analysis.
10. The method of claim 8 which is RT-PCR.
11. The method of claim 8 which is *in situ* hybridization.

12. The method of claim 8 which is gridding.
13. The diagnostic method of claim 8 in which cancer is prostate cancer.
14. The diagnostic method of claim 8 which is for BPH.
15. A method for identifying compounds which bind to and inhibit or activate PLA₂ using an enzymatic assay specific for PLA₂.
16. A method for inducing an immunological response in an animal which comprises inoculating the animal with PLA₂, or a fragment or variant thereof, adequate to produce antibody to protect said animal from cancer.
17. A method for inducing an immunological response in an animal which comprises inoculating the animal with PLA₂ to produce antibody to be used in a diagnostic test for cancer, particularly prostate cancer, and BPH.
18. A method for the production of transgenic animals with altered PLA₂ levels for the production of animals bearing PLA₂ induced diseases.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/13550

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/00; C12N 9/00, 9/20
US CL : 514/2; 435/183, 198

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. :

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOTECHABS, BIOTECHDS, CJACS, DDFU, DRUGU, APS
search terms:cancer, plaz, phospholipase a2, prostate, treat, antagonist

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	DE SOUZA et al. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. Br. J. Cancer. 1997, Vol. 75, No. 11, pages 1593-1600, see especially pages 1593 and 1599.	1,2
A	MURATA et al. Expression of group-II phospholipase A ₂ in malignant and non-malignant human gastric mucosa. Br. J. Cancer. 1993, Vol. 68, pages 103-111, see especially pages 109-111.	1,2
A	WO 94/00766 A1 (AUCKLAND UNISERVICES LIMITED) 06 January 1994, page 2, lines 19-24, page 25, lines 9-16 and Figure 4	1,2

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application best cited to understand the principle or theory underlying the invention.
*'A'		document defining the general state of the art which is not considered to be of particular relevance
*'E'	X	earlier document published on or after the international filing date
*'L'		document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
*'O'		document referring to an oral disclosure, use, exhibition or other means
*'P'		document published prior to the international filing date but later than the priority date claimed
	Y	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	Z	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	E	document member of the same patent family

Date of the actual completion of the international search Date of mailing of the international search report
16 SEPTEMBER 1997 29 OCT 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
SUSAN UNGAR
Telephone No. (703) 308-0196

Jacob
Fur

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/13550

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/13550

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-2 are drawn to a method of treating cancer by administering a PLA2 antagonist.
Group II, claims 3-7 are drawn to a diagnostic method for a cancer comprising analyzing for abnormally high levels of PLA2 polypeptide.
Group III, claims 8-14 are drawn to a diagnostic method for a cancer or BPH comprising analyzing for abnormally high or low transcription levels of PLA2.
Group IV, claim 15 is drawn to a method for identifying compounds which bind to and inhibit or activate PLA2.
Group V, claims 16 and 17 are drawn to a method for inducing an immunological response in an animal comprising inoculating an animal with PLA2 or a fragment or variant thereof.
Group VI, claim 18 is drawn to a method for the production of transgenic animals with altered PLA2 levels of production.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2 they lack the same or corresponding special technical features for the following reasons: the claims of inventions II-VI are drawn to different methods which do not relate to the special technical feature of treating cancer by administering a PLA2 antagonist recited in Group I.